Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
21.51
-0.87 (-3.89%)
May 13, 2026, 3:17 PM EDT - Market open
Bicara Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Bicara Therapeutics stock have a consensus rating of "Buy" and an average price target of $30.27, which forecasts a 40.73% increase in the stock price over the next year. The lowest target is $16 and the highest is $42.
Price Target: $30.27 (+40.73%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Bicara Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 3 | 3 | 4 |
| Buy | 3 | 4 | 4 | 3 | 3 | 4 |
| Hold | 2 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 8 | 9 | 9 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $16 → $18 | Hold | Maintains | $16 → $18 | -16.32% | May 12, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $36 → $37 | Buy | Maintains | $36 → $37 | +72.01% | May 12, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +95.26% | May 11, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $16 | Hold | Maintains | $14 → $16 | -25.62% | Mar 31, 2026 |
| Wedbush | Wedbush | Buy Reiterates $30 | Buy | Reiterates | $30 | +39.47% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.79
from -2.52
EPS Next Year
-3.15
from -2.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.54 | -2.29 | ||||||
| Avg | -2.79 | -3.15 | ||||||
| Low | -3.42 | -4.05 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.